Trofinetide Adverse Events: What the Label and Studies Report

This page summarises what product labeling and the published literature have reported about adverse events associated with trofinetide. It describes findings only and makes no judgement about tolerability for any individual. This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician about any symptom, medicine or treatment decision.

What trofinetide is, at label level

Trofinetide is a prescription medicine and a synthetic analogue of the tripeptide glycine-proline-glutamate, which is derived from insulin-like growth factor 1; a 2024 review of peptide and oligonucleotide approvals described its 2023 United States approval for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older (PMID 38399458). A 2023 pharmacology review summarised the development programme and the rationale for studying the compound in Rett syndrome, a neurodevelopmental disorder associated with MECP2 variants (PMID 38035006). Rett syndrome is the only approved indication; any other application discussed in the literature is investigational.

This page does not contain dosing directions, administration instructions or product sourcing information. Those belong to the prescribing clinician and the official prescribing information.

Boxed warning status and labeled warnings

The United States prescribing information for trofinetide does not carry a boxed warning. The Warnings and Precautions section of that labeling lists two items: diarrhea and weight loss. Both correspond to signals that appeared in the registrational programme, where researchers reported diarrhea as the most common treatment-emergent adverse event in the placebo-controlled phase 3 study (PMID 37291210). The most frequently reported adverse reactions described in the trial literature were gastrointestinal, principally diarrhea and vomiting (PMID 37291210).

How the evidence base was built

The design paper for LAVENDER described a randomized, double-blind, placebo-controlled phase 3 study conducted over 12 weeks in females with Rett syndrome aged 5 to 20 years, with caregiver-reported and clinician-reported outcome measures as endpoints (PMID 35149233). The results of that randomized phase 3 study were published in 2023 and reported both efficacy outcomes and the treatment-emergent adverse event profile (PMID 37291210). Participants who completed the controlled phase could enter open-label extensions: the LILAC study reported longer-term safety and efficacy outcomes (PMID 38917793), and the LILAC-2 study reported results from a 32-month open-label period (PMID 39025065). A pooled meta-analysis of efficacy and safety followed (PMID 38771525), and a real-world study named LOTUS examined benefits and tolerability outside the controlled trial setting (PMID 40936177).

Gastrointestinal Adverse Events: What Studies Report

Gastrointestinal events dominated the adverse event tables in every published trial report. In the randomized phase 3 study, researchers reported diarrhea and vomiting as the most common treatment-emergent adverse events and reported them more frequently in the trofinetide group than in the placebo group over the 12-week double-blind period (PMID 37291210). The study design paper had prespecified safety and tolerability assessment alongside the co-primary efficacy endpoints across the 12-week treatment period (PMID 35149233).

In the LILAC open-label extension, researchers again reported diarrhea as the most commonly recorded treatment-emergent adverse event among participants who continued treatment after the controlled phase (PMID 38917793). The longer LILAC-2 report, covering a 32-month open-label period, described the long-term safety profile as consistent with what had been recorded earlier, with gastrointestinal events remaining the most frequently reported category (PMID 39025065). The pooled meta-analysis reported that adverse events, led by diarrhea and vomiting, occurred more often with trofinetide than with placebo across the randomized data it combined (PMID 38771525).

Because Rett syndrome itself is associated with gastrointestinal and feeding difficulties, the trial reports recorded events as treatment-emergent rather than as attributed causally to the medicine; the phase 3 report presented adverse events by treatment arm so that the placebo comparison was visible (PMID 37291210).

Weight Loss and Nutrition: What Studies Report

Weight loss appears in the labeled Warnings and Precautions alongside diarrhea. In the randomized phase 3 study, researchers reported weight-related adverse events among the treatment-emergent findings monitored during the 12-week controlled period (PMID 37291210), and the design publication described safety monitoring that extended across the full treatment period (PMID 35149233). The open-label extension reports continued to track safety over longer exposure, with LILAC-2 reporting outcomes across 32 months of open-label treatment (PMID 39025065). Nutritional status and growth in this population are clinical matters for the treating team rather than topics this page can individualise.

Discontinuations and Dose Reductions: What Studies Report

Tolerability in the trial programme was measured partly by how many participants stopped treatment. In the randomized phase 3 study, researchers reported that discontinuations due to adverse events occurred more often in the trofinetide group than in the placebo group, with diarrhea the leading reason recorded (PMID 37291210). The LILAC open-label extension reported discontinuations and the adverse events that preceded them among participants who continued beyond the controlled phase (PMID 38917793), and LILAC-2 reported retention and safety outcomes across its 32-month open-label period (PMID 39025065). The pooled meta-analysis also examined withdrawal related to adverse events when combining randomized data (PMID 38771525).

Real-World Observations: What Studies Report

The LOTUS study examined trofinetide outside the controlled trial setting and reported on both perceived benefits and tolerability in routine use for Rett syndrome (PMID 40936177). Real-world reports differ from randomized data in important ways: there is no placebo comparison, reporting is not blinded, and the populations may be broader than trial eligibility criteria allowed, which the controlled phase 3 study had restricted to females aged 5 to 20 years (PMID 35149233).

Exposure, Special Populations and Pharmacokinetics: What Studies Report

Several publications addressed how trofinetide exposure varies by population, which is relevant to how adverse events are interpreted but is not a tolerability finding in itself. Researchers built a population pharmacokinetic model to support dosing across the treated population (PMID 39692836) and a separate population pharmacokinetic analysis in a pediatric population aged 2 to 4 years with Rett syndrome (PMID 39692837). An exposure-response analysis modelled the relationship between drug exposure and efficacy measures in individuals with Rett syndrome (PMID 38363467). An in silico physiologically based pharmacokinetic study estimated how hepatic impairment would be expected to affect trofinetide exposures (PMID 38963587). None of these modelling papers substitutes for the safety data collected in the clinical studies, and none of them supports any individual dosing decision, which remains with the prescriber.

Summary table of the cited studies

What the published record does not settle

• Adverse event rates recorded in a 12-week controlled study cannot be extrapolated to indefinite use; the design paper defined that period explicitly (PMID 35149233), and longer follow-up came from open-label designs without a placebo arm (PMID 39025065).
• Open-label extensions enrol participants who tolerated earlier treatment, which can shape the adverse event picture reported in those cohorts (PMID 38917793).
• Pooled analyses are limited by the number and size of the randomized studies available to combine (PMID 38771525).
• Modelling papers describe estimated exposures rather than observed clinical outcomes (PMID 38963587).

Where symptom questions belong

Adverse event tables describe groups of trial participants, not individuals. Any new, persistent or worsening symptom during prescribed treatment, including diarrhea, vomiting, reduced intake or weight change, is a matter for the prescribing clinician, who holds the full medical history and the official prescribing information. Nothing on this page describes who should or should not receive trofinetide, and nothing here supports use outside the approved indication, which remains investigational in any other setting (PMID 38399458).

References

• Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study (Nature Medicine, 2023)
• Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome (Contemporary Clinical Trials, 2022)
• Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study (Med, 2024)
• Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study (Med, 2024)
• A meta-analysis of the efficacy and safety of trofinetide in patients with Rett syndrome (Neurological Sciences, 2024)
• Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study (Developmental Medicine and Child Neurology, 2026)
• Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model (Advances in Therapy, 2024)
• Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome (Advances in Therapy, 2024)
• Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome (Advances in Therapy, 2025)
• Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome (Advances in Therapy, 2025)
• Trofinetide: a new chapter in Rett syndrome's treatment (Frontiers in Pharmacology, 2023)
• 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest (Pharmaceuticals, 2024)